Introduction

P
reterm birth has been identified as a major public health issue around the world. According to a recent WHO report, 1 preterm birth rates are increasing in almost all countries worldwide. Possible reasons for this include increases in maternal age and underlying maternal health problems, such as diabetes or hypertensive disorders, the rising use of infertility treatments resulting in increased rates of multiple pregnancies or changes in obstetric practice, such as more caesarean births before term. 2 Prematurity, which is often inter-related with small-for-gestational-age babies, is the leading cause of newborn deaths. Furthermore, premature birth is associated with high short-term and long-term costs.
A number of predisposing factors have been identified as being associated with preterm birth. These include demographic and lifestyle factors (e.g. maternal age, low socioeconomic status, ethnicity, obesity, substance abuse, stress and lack of social support) and 'medical' risk factors, such as multiple pregnancies, prior preterm birth or pregnancy termination, vaginal infections and chronic conditions, such as diabetes, high blood pressure or coagulopathy. There is also a genetic influence. However, the precise cause often remains unidentified. [2] [3] [4] [5] In Austria, recent data have indicated rising rates of preterm births. 6 Between 1999 and 2010, the percentage of preterm-born children with a birth weight below 2500 g rose from 6.5 to 7%, relating to an absolute number of 5048-5549 of 78 138 and 78 742 total live births, respectively. In total, 10.9% of children were born <37 weeks of gestation. According to this data, Austria has a high preterm birth rate compared with other European countries.
Recently, child health has become a top priority on the political agenda and resources have been devoted to developing preventive maternal and child health programmes that address current needs. 7, 8 Health policy makers and decision makers, therefore, require objective and transparent information about effective measures on how to prevent preterm birth. Furthermore, against the backdrop of limited resources, they need information on the efficiency, costs and affordability of such measures.
A vast number of high-quality systematic reviews evaluating the impact of different antenatal approaches on preterm birth exist. They have recently been summarized in an overview. 9 Furthermore, there are some economic evaluations on these measures, which have also been summed up in review. 10 While no benefit (e.g. repeated digital cervical assessment for risk assessment) or negative effects (e.g. oestrogen supplementation) with respect to preterm birth were demonstrated for the majority of interventions, some approaches were identified as promising in terms of efficacy and cost effectiveness (e.g. lower genital tract infection screening, progesterone injection in women with prior preterm births).
To address the affordability of such programmes, this article presents the results of a budget impact analysis on measures to prevent preterm births <34 weeks in Austria that have been selected from among these promising approaches.
Methods
Selection of measures to prevent preterm birth
On the basis of the two systematic literature reviews on the effectiveness 9 and cost effectiveness 10 of measures to prevent preterm birth mentioned earlier, we first selected approaches that promised to be effective and-if economic evaluations were available-cost effective. Working together with national medical experts, a consensus was reached on five approaches to be selected for the budget impact analysis, which are based on the criterion of feasibility and take into account the characteristics of pregnant women in Austria: (i) screening for shortened cervix of pregnant women at risk of preterm birth (previous spontaneous preterm birth) and vaginal progesterone application; (ii) progesterone injection for pregnant women at risk of preterm birth (previous spontaneous preterm birth); (iii) polyunsaturated fatty acid supplementation ('fish oil') for pregnant women at risk of preterm birth (previous spontaneous preterm birth, smokers, status post-growth retardation); (iv) smoking cessation for pregnant smokers (cognitive behavioural approach and 'feedback approach') and (v) universal screening for asymptomatic vaginal infection. Details on the programmes are presented in table 1 .
Methodological details of the budget impact analysis
We undertook a budget impact analysis according to methodological standards, 11 where we compared each of the five programmes with the alternative 'no preventive measure'. The latter was chosen because although preventive measures are already in place to some extent, they are provided inconsistently and partly for target populations that are not evidence-based (e.g. for all pregnant women, in contrast to those with previous preterm births). Hence, it was assumed that the monetary benefits will currently be outweighed by additional costs elsewhere. The budget impact was calculated for a 1-year and 5-year time horizon from a public payer's perspective in an undiscounted form. This implies that we measured direct costs only. According to the Austrian Manual on Health Technology Assessment, 12 one-time costs for investment and the establishment of a programme are not included in the calculation.
In detail, we first estimated the costs for each programme and added the costs for preterm births. The total costs for preterm birth with and without the preventive measure were derived by estimating the expected numbers of preterm births <34 weeks of gestation with and without the preventive measure based on decision trees (see Appendix 1, Supplementary material online for details). The number of preterm births with and without the preventive programme was multiplied by the unit costs of preterm birth. The budget impact was calculated by demonstrating the resulting total costs for the preventive measures compared with the alternative 'no preventive measure'. As a final result, potential savings or extra costs were displayed.
Data sources and sensitivity analysis
Data sources for effectiveness were systematic reviews on effectiveness supplemented by assumptions when data were lacking. Data sources for the type of resources used were clinical guidelines, data from the systematic review on economic evaluations 10 and expert opinions on the state of the art of service supply. Information on the quantities of resources required was derived from birth registry data 13 and from a review on epidemiological data that gave us information on the size of the target population.
14 The target population was held stable over the 5-year time horizon because, first, the birth rate has not shown a clear upward or downward trend over the last years and, second, we assumed there would not be major changes in lifestyle (e.g. number of pregnant smokers) during the following 5 years. Data sources for unit costs on preventive measures are public national tariffs (e.g. on vaginal smears, vaginal ultrasound scans). We derived costs of preterm births from a published national study. 15 They include hospital cost at birth and hospital outpatient cost for 5 years after birth.
All parameters that were uncertain or based on assumptions were varied in one-way sensitivity analyses. A total list of parameters that were used for the intervention and the reference scenarios, their values and ranges, as well as their sources is available in the Appendix 2 (Supplementary material online). Table 2 illustrates the costs for the different preventive programmes, the total costs, the cost differences to the alternative 'no preventive programme' and the number of preterm births prevented. The figures refer to the results from the base-case analysis. Concerning direct programme costs, the lowest costs have been estimated for the programme 'cervix screening' (E34 000 per year). The most expensive programme is the universal infection screening ($E500 600). All other programmes cost between E100 000 and E200 000 per year in the base-case analysis.
Results
Base-case results
According to the base-case results from the decision tree analysis, the largest numbers of preterm births <34 weeks are to be prevented by the universal infection screening, where more than 200 fewer preterm births per year have been estimated. This would equal 1200 fewer preterm births in 5 years. The smoking cessation programmes are associated with the lowest numbers of prevented preterm births (<15 in 1 year and <70 in 5 years). The remaining programmes have resulted in an estimated number of 60-100 preterm births prevented in 1 year and 300-450 in 5 years.
Total
The cost differences between the prevention programme and the alternative 'no preventive measure' in the base-case analysis are all in favour of the preventive measures. This means that when taking the costs of preterm births avoided into account, the prevention programme is overall less costly than doing nothing. We estimated the largest cost difference for the universal infection screening programme (ÀE13 and ÀE71 million in 1 year and after 5 years, respectively). The smallest cost difference has been demonstrated for the smoking cessation programmes, where the potential savings are around ÀE500 000 in year 1 and five times this amount in year 5. In the remaining programmes, the differences lie between ÀE3 and ÀE5 million in 1 year and between ÀE19 and ÀE28 million after 5 years.
Sensitivity analysis
We varied uncertain parameters in sensitivity analyses. Uncertain parameters were those that were either based on assumptions due to lack of detailed data (e.g. unit costs for new services which have not existed so far), which showed wide intervals, for example, due to different values presented in the literature (e.g. for cost of preterm birth) or that were from international sources (e.g. probability for cervix length 15 mm). The parameters finally chosen for sensitivity analysis include the programmes' effectiveness, the hospital costs of preterm birth, uptake of and/or compliance to the programmes, the size of the target population and unit costs of service components within the preventive measure in cases where detailed tariffs were missing. In addition, we ran the model with a best case and a worst case scenario. The best case and worst case scenarios combine parameter values with respect to size of the target group, programme effectiveness and hospital costs of preterm births in their most optimistic and most pessimistic values, respectively.
The ranges in terms of expected preterm births prevented are presented in table 2 for a 1-year and 5-year perspective. Depending on the type of programme, the lower range for the reduction of premature births ranges from À3 (smoking cessation) to À229 (infection screening) in year 1 and from À14 to À1144 in year 5. In the best case scenarios, between 21 and 248 prevented preterm births have been estimated in year 1, corresponding to 104 and 1238 fewer preterm births in year 5. Figure 1 illustrates the variations in total cost differences between the preventive measure and the alternative 'no preventive measure' for a 5-year time horizon. The results show that the hospital costs of preterm birth considerably influence the cost differences regardless Table 2 Prevented preterm births and total costs of programmes in 1 and 5 years CBT: cognitive behavioural therapy.
of prevention programme. Lower hospital costs reduce the potential savings. In the 'smoking cessation programmes' and in the 'fish oil programme', results are additionally influenced by the size of the assumed target group. The larger the treated population, the larger the potential savings are. The unit costs of specific screening or treatment elements have varying influence on the total cost differences. While higher costs of infection screening increase the programme costs from E500 000 to E2 million per year (figure not shown), the influence on the total cost difference is marginal. On the contrary, higher costs of behavioural therapy in the smoking cessation programme have a strong (and unfavourable) impact on the overall cost differences between implementing the programme and the alternative 'no programme'. Overall, with the exception of the 'fish oil programme' (in the case of low compliance) and the 'CBT-smoking cessation programme' (in the case of low costs for premature birth, high unit costs for the therapy and small target group), the total costs of the prevention approaches are considerably lower than without the programme, even in the worst case scenarios.
Discussion
In this article, we presented a budget impact analysis for five approaches to prevent preterm birth of <34 weeks of gestation. The results have shown that the different programmes vary greatly in regard to programme costs, preterm births prevented, total costs and potential cost savings.
The cheapest option seems to be to implement a cervix screening programme for women with previous spontaneous preterm births (below E50 000 per year), while the most expensive alternative would be a universal infection screening, costing between E500 000 and E2 million, depending on the size of unit costs assumed.
If single measures are introduced, preterm births <34 weeks are expected to be reduced by a maximum of 248 per year, which equals 11% of all preterm births <34 weeks. Yet, because of the large costs of premature birth-except for very few pessimistic scenarios in the 'fish oil programme' and 'CBT-smoking cessation programme'-all preventive measures are, in total, less costly than not implementing a prevention programme. Because of the larger number of expected prevented preterm births, the biggest cost savings can be expected from universal infection screening, whereas the lowest potential savings have been estimated for the smoking cessation programmes.
Comparison with international and other national studies is limited, as the existing literature addresses cost effectiveness but not the budget impact of measures to prevent preterm births.
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The cost-effectiveness results seem to complement the results of our analysis, as they consistently favoured the preventive measure analysed. However, only one study 16 compared all relevant alternatives in their economic evaluation and the transferability of cost-effectiveness results to Austria is limited.
The study has a number of limitations. First, because the purpose of a budget impact analysis is to analyse the affordability of a technology, our results are of limited value for resource allocation decisions in terms of efficiency. For that purpose, an economic evaluation (e.g. cost-effectiveness analysis) would be required, thus taking a broader range of health effects (e.g. morbidity, mortality and quality of life) and a different time horizon into account. Our hypothesis, which still needs to be confirmed, is that the cervix screening programme and the infection screening programme seem to dominate the 'fish oil approach', the two smoking cessation programmes and the 'progesterone injection approach'. The second limitation refers to the costs included in our analysis. Some of the cost data used are uncertain, which has, however been accounted for in the sensitivity analyses. Moreover, the costs for programme implementation and one-time investments have been neglected, meaning that the true public expenditure for the programmes will actually be higher than in our analysis. Yet, this is counterbalanced by not including long-term costs of premature births due to the lack of reliable data. In this case, our results are biased against the intervention, as higher costs of preterm birth would have resulted in even higher potential cost savings.
Third, the cost savings need to be interpreted with caution, because existing infrastructure and personnel cannot immediately be reduced in the case of decreasing numbers of preterm births.
Fourth, the alternative scenarios chosen ('no preventive measure') may not totally reflect the real-world situation in Austria, as many of the measures analysed may already have been implemented in some cases. However, if at all, they are done in a non-standardized manner, and patients other than those we did the calculations for may undergo the preventive measure (e.g. progesterone injection for twin pregnancies instead of single pregnancies). This influences the results in two directions. First, the incremental programme costs (compared with no preventive measure) may in fact be lower because the interventions have already been carried out on some patients. Similarly, in those cases where appropriate patients have already been treated in the appropriate way, the health effects in terms of preterm births prevented may also be lower in real life. This will, however, be balanced by those cases where inappropriate patients are treated (e.g. progesterone injections for women with any type of preterm birth, instead of spontaneous preterm birth) or the treatment is done in the wrong way (e.g. infection screening for bacterial infections only).
Furthermore, the effectiveness of the programmes with respect to preterm births prevented is largely based on systematic reviews of international clinical trials. Due to their limited external validity, the effect of the programmes may be lower in a 'real-world screening programme' and the transferability to the Austrian setting may be limited. Yet, because of the high costs of premature birth and the comparably 'low' costs of the screening programmes, the potential savings very likely outweigh the costs in most of the programmes analysed. Further analyses should take combined approaches that may have the potential to further reduce the number of preterm births into account.
Finally, as the overview of systematic reviews on measures to prevent preterm birth shows, 9 there are further approaches showing promising effects on preterm births which merit consideration for a budget impact analysis in future. Not least, some novel approaches that have been discussed more recently, such as preconceptional care, will also require attention; however, they have not undergone rigorous effectiveness evaluation so far. 22 Furthermore, because we focussed on the prevention of spontaneous preterm birth, we restricted the analysis to preterm births <34 weeks of gestation, when most of the spontaneous preterm births occur in Austria. Future studies will have to pay attention to measures that take into account preterm births up to 37 weeks of gestation including provider-initiated preterm births.
In conclusion, our results are robust concerning the overall positive economic net effect, suggesting the affordability of all the programmes analysed in Austria. Because of similar trends concerning preterm birth and the generally high costs of preterm births, comparable results can be expected for other European countries. In addition, the programmes have demonstrated a high potential to reduce hospital cost burden, which is a priority in many healthcare systems. Compared with other healthcare technologies often showing much less favourable results, the implementation of such a programme should be considered, with cervix screening and infection screening being the most promising in candidates in Austria.
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Key points
Preterm birth has become a growing public health issue all over Europe. Several preventive measures are promising in terms of effectiveness and cost-effectiveness evidence. If implemented for the appropriate target groups in Austria, a number of preventive programmes show higher potential cost savings than programme costs. Prevention of preterm birth seems affordable and short-term benefits can be expected for a selected number of prevention programmes. The general conclusion likely applies to other European countries with a similar healthcare system structure and service provision level.
